文献速递主动脉疾病

Zenith Alpha 腹主动脉腔内移植物加拿大上市后研究

A Canadian postmarket study of the Zenith Alpha Abdominal Endovascular Graft.
PubMed 文献 · J Vasc Surg · 2025-01-30

在加拿大5个中心开展前瞻性、多中心、非随机上市后研究,2017年5月至2018年6月纳入100例腹主动脉或主髂动脉瘤患者,使用Zenith Alpha腹主动脉腔内移植物并随访2年。技术成功率为99%(98/99),2年随访器械成功率为86.9%(86/99),无开放转术,无器械或手术相关死亡,I型内漏发生率低,结果支持该器械的安全性和性能。

要点

  • 技术成功率99%(98/99),唯一技术失败为主体移植物部分覆盖左肾动脉。
  • 2年随访器械成功率86.9%(86/99),无开放转术,无器械或手术相关死亡。
  • 随访期间4例发生I型内漏,无III型或IV型内漏。

核心结论

  • Zenith Alpha腹主动脉腔内移植物在腹主动脉或主髂动脉瘤修复中表现出高技术成功率、无开放转术和无动脉瘤相关死亡,I型内漏发生率低,这些结果支持该器械的安全性和性能。

研究设计与样本

  • 前瞻性、多中心、非随机上市后研究,在加拿大5个中心开展,时间为2017年5月至2018年6月。
  • 共纳入100例腹主动脉或主髂动脉瘤患者,使用Zenith Alpha腹主动脉腔内移植物,按各机构标准诊疗随访2年。

主要发现

  • 患者平均年龄75.2±7.4岁,88%为男性,16%为主髂动脉瘤。
  • 技术成功率为99%(98/99),1例因数据缺失被排除出技术成功终点,唯一技术失败为主体移植物部分覆盖左肾动脉。
  • 平均随访时长635.9±213.6天,2年随访器械成功率为86.9%(86/99)。
  • 共发生9例死亡,均与器械或手术无关;无患者需转为开放手术;随访期间4例发生I型内漏,无III型或IV型内漏。
  • 8例随访期间动脉瘤增长>5 mm;5例发生髂支移植物闭塞;共14例患者接受15次二次干预(SIs)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the performance of the low-profile Zenith Alpha Abdominal Endovascular Graft in a Canadian postmarket setting. METHODS: A prospective, multicenter, nonrandomized, postmarket study was conducted at five sites in Canada between May 2017 and June 2018. Patients were treated for abdominal aortic or aortoiliac aneurysms using the Zenith Alpha Abdominal Endovascular Graft and followed for 2 years after the initial procedure in accordance with each institution's standard of care. RESULTS: A total of 100 patients (mean age, 75.2 ± 7.4 years,; 88% male; 16% with aortoiliac aneurysms) were treated. Technical success was achieved in 99% of patients (98/99). One patient was excluded from the technical success end point owing to missing data. The single technical failure was due to partial coverage of the left renal artery by the main body graft. The mean follow-up duration was 635.9 ± 213.6 days. Device success through the 2-year follow-up was achieved in 86.9% of patients (86/99). Overall, nine deaths occurred; none were related to the study device or the procedure. No patient required conversion to open surgery. Through follow-up, four patients experienced a type I endoleak. There were no instances of type III or IV endoleaks. One case of aneurysm rupture (related to type Ib endoleak and retrograde migration of an iliac leg graft) was treated successfully with angioplasty, coil embolization, and iliac graft extension. Eight patients experienced aneurysm growth of >5 mm throughout follow-up. Iliac leg graft occlusions occurred in five patients. In total, 14 patients required 15 secondary interventions (SIs). Iliac leg graft-related SIs were performed in seven patients, for device occlusion (n = 3), kink or compression (n = 2), stenosis (n = 2), or nonocclusive thrombus (n = 3). Other reasons for SIs included type II endoleak (n = 8), type Ib endoleak (n = 2), iliac artery dissection (n = 1), abdominal aortic aneurysm rupture (n = 1), and partial coverage of the left renal artery (n = 1). CONCLUSIONS: The Zenith Alpha Abdominal Endovascular Graft demonstrates high rates of technical success, no open conversions, and no aneurysm -related mortality after abdominal aortic or aortoiliac aneurysm repair. Type I endoleak rates were low. These outcomes support the safety and performance of the Zenith Alpha Abdominal Endovascular Graft.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lindsay TF, Harlock J, Herman C, et al. A Canadian postmarket study of the Zenith Alpha Abdominal Endovascular Graft. J Vasc Surg. 2025. PMID: 39892792. doi:10.1016/j.jvs.2025.01.196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。